Stockwinners Market Radar for November 09, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:09 EST Cathie Wood's ARK Investment bought 40K shares of Tesla today

20:06 EST Cathie Wood's ARK Investment bought 333K shares of Roblox today

19:52 EST Montauk Renewables reports Q3 RNG production down 4.8% y/y at 1.4M MMBTu

18:22 EST Dutch Bros CEO: No good news on inflation - In an interview on CNBC's Mad Money, Joth Ricci said the market has thrown Dutch Bros some challenges, but the team has responded. He is not seeing any big relief on the inflation front and expects it to remain high for a while. The company executed a price increase in September, but it was received "pretty well," he added. Ricci expects to add 150 shops in 2023. He said the company is "growing based on our people readiness."

17:56 EST O'Reilly Automotive director sells $9.2M in common stock - In a regulatory filing, O'Reilly Automotive disclosed that its director Lawrence O'Reilly sold 11K shares of common stock on November 7th in a total transaction size of $9.2M.

17:41 EST Beyond Meat sees Q4 operating expenses mid-$60M range - Sees Q4 gross margin negative. Says expects cash used in operating activities to increase in Q4. Says expects cash flow from operations to be positive in second half of FY23. Says in current environment not seeing benefit from competition. Says significantly reducing operating expenses. Says reduced operating expenses 23% from Q1. Says expects operating expenses to fall further in Q4 and thereafter. Comments and guidance taken from Q3 earnings conference call.

17:33 EST Excelerate Energy raises FY22 adjusted EBITDA view to $264M-$274M - Prior guidance was $249M-$269M.

17:28 EST Nortech Systems says carrying momentum into 2023 - CEO Jay Miller says: "We are optimistic about a strong finish to this year and carrying that momentum into 2023. Monthly bookings remain strong and the markets we serve are anticipating continued growth in 2023. That said, we are carefully monitoring potential macroeconomic headwinds. Nortech will take action as needed to adapt to changing market conditions while we continue to deliver the highest quality products to our mission-critical medical, industrial, and defense customers."

17:17 EST PureCycle Technologies provides Q3 update - PureCycle Technologies announced a corporate update and financial results for the Q3. Highlights include: flagship purification facility in Ironton, Ohio, targeting mechanical completion and pellet production in the Q1 of 2023; closed on offtake agreements representing 106.0 million pounds of ultra-pure recycled resin bringing total signed offtake agreements to 111% of nameplate capacity for Augusta lines 1 and 2; finalized its Joint Venture Agreement with SK geo centric to develop a purification facility in Ulsan, South Korea; and financing to fund Augusta's first two purification lines and three East Coast preprocessing facilities targeted for completion by year-end with PureCycle evaluating scenarios with the objective of maintaining optionality in its capital structure as it moves to operational revenue in 2023. As of September 30 PureCycle had total liquidity of $416.1M including $215.0M of cash, cash equivalents and debt securities available for sale and $201.1M in restricted cash.

17:00 EST LianBio doses 1st patient in Phase 1 of BBP-398 in Chinese patients with tumors - LianBio announced the first patient has been dosed in its Phase 1 clinical trial of BBP-398, a SHP2 inhibitor, in Chinese patients with advanced solid tumors.SHP2 is a protein-tyrosine phosphatase that links growth factor, cytokine and integrin signaling with the downstream RAS/MAPK pathway to regulate cellular proliferation and survival. Overactivity of SHP2 is a critical contributor to many forms of cancer, is a mechanism of resistance to several targeted therapies, and can suppress antitumor immunity.In this two-part, open label, dose escalation and dose expansion Phase 1 study, safety and preliminary anti-tumor activity will be examined. Part 1 is a dose escalation to establish the recommended Phase 2 dose ( of BBP-398 and assess the pharmacokinetic profile of BBP-398 in Chinese patients. Part 2 is a dose expansion to examine preliminary antitumor activity in patients with advanced or metastatic EGFR-mutant non-small cell lung cancer/"SHP2 inhibition has the potential to overcome resistance mechanisms to various important standard of care cancer therapies," said Yizhe Wang, Ph.D., Chief Executive Officer of LianBio. "Data generated to date suggest BBP-398 has a promising pharmacokinetic profile that could provide key advantages as a backbone combination therapy. Chinese NSCLC patients have approximately 2-3-fold higher EGFR mutation rate than Western patients, and while EGFR inhibitors represent an important advancement in treatment, many patients go on to develop treatment-resistant disease. We look forward to conducting this monotherapy study and progressing BBP-398 into combination trials with an EGFR inhibitor beginning in 2023."

16:57 EST RingCentral jumps 9% to $31.08 after Q3 results beat ests, FY22 EPS view raised

16:54 EST Artisan Partners reports October AUM of $125.3B - Artisan Partners reported that its preliminary assets under management as of October 31 totaled $125.3B. Artisan Funds and Artisan Global Funds accounted for $60.1B of total firm AUM, while separate accounts and other AUM1 accounted for $65.2B.

16:47 EST Canoo sees Q4 operating expenses $70M-$90M - Sees Q4 capital expenditures $30M-$50M.

16:45 EST Rivian Automotive rallies 7% to $30.02 after keeping production outlook

16:44 EST IO Biotech: Cash on hand expected to support operations through mid-2024 - Cash on hand is expected to support operations through anticipated data readouts into mid-2024.

16:38 EST Atmos Energy raises annual dividend 8.7% to $2.96 - The company's Board of Directors has declared a quarterly dividend of $0.74 per common share. The indicated annual dividend for fiscal 2023 is $2.96, which represents an 8.8% increase over fiscal 2022.

16:35 EST Pfsweb trading resumes

16:31 EST Advantage Solutions cuts FY22 adjusted EBITDA view to $430M-$440M - Previous guidance was $490M-$510M.

16:30 EST Imago BioSciences sees cash runway extending into 2025

16:28 EST PFSweb announces $4.50 per share special dividend - PFSweb announced that it continues to work with its financial advisor, Raymond James, on a review of a full range of strategic alternatives for its PFS business. Mike Willoughby, CEO of PFSweb, said: "While the completion of our strategic evaluation has been slowed by a combination of macroeconomic headwinds and the need to complete our internal restructuring, we have made great strides to streamline our organization through right-sizing corporate SG&A and addressing the excess cash on our balance sheet from the LiveArea transaction. We believe these initiatives, along with our expectation of continued strong growth in service fee revenue and profitability, will allow us to continue our strategic alternatives process in 2023 on a much stronger footing. We remain focused on maximizing value for our shareholders. "Given the substantial excess cash generated from the LiveArea divestiture, we believe a special dividend is the optimal pathway to return capital to our shareholders. In fact, we believe we can best position our strategic review process for success by returning excess cash and maintaining more traditional levels of operating liquidity." The company does not intend to comment further regarding the process unless there are material developments to discuss. The company's board has approved a $4.50 per share special dividend, returning approximately $111M of capital from the LiveArea divestiture to shareholders. The dividend is payable on December 15 to shareholders of record as of December 1.

16:27 EST Tuya announces $50M share repurchase program - Tuya announced that its board of directors has authorized a share repurchase program under which the company may repurchase up to $50M of its Class A ordinary shares, including in the form of American depositary shares.

16:25 EST Virtus Investment reports preliminary AUM $149.5B as of October 31 - In addition, the company provided services to $2.5B of other fee-earning assets, which are not included in assets under management.

16:23 EST AllianceBernstein reports preliminary AUM $627B as of October 31 - Up from $613B at the end of September. The 2% AUM increase was driven by market appreciation, partially offset by net outflows in each channel.

16:19 EST Switch says deal with DigitalBridge Group set to close in Q4 - Switch previously announced it has entered into a definitive agreement with DigitalBridge Group, Inc., under which DigitalBridge Partners II and an affiliate of global infrastructure investor IFM Investors will acquire all outstanding common shares of Switch for $34.25 per share in an all-cash transaction valued at approximately $11 billion, including the assumption of debt. The transaction was approved by Switch stockholders on August 4, 2022. In addition, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to the transaction occurred on July 28, 2022. The transaction is expected to close in the fourth quarter of 2022. Completion of the transaction is subject to the satisfaction of the remaining closing conditions. Due to the pending merger transaction, Switch management is not providing new guidance or affirming past guidance at this time.

16:16 EST Rivian Automotive: Net R1 preorder backlog over 114,000 at November 7

16:16 EST Arena Group expects to be EBITDA positive in Q4 - Ross Levinsohn, Chairman and CEO says: "This is a watershed quarter for the company with record revenue, lower costs, audience and advertising growth with increasing yield and profitability. We expect our Adjusted EBITDA to be positive in the fourth quarter and for the full year with expanding audiences, higher revenue, and operational efficiency. The investments we made over the past two years have driven our success, growth, and opportunity for the coming years. Our playbook facilitates cross-promotion, real time coverage and in-depth analysis, and success in one part of our business drives improvements across the board. As a key component of this, acquisitions that are integrated into our platform generate significant growth over historical levels, while simultaneously expanding profit margins. We proved this last year with The Spun, and repeated it with Parade and plan to do so with The Morning Read. The challenging media landscape is creating significant M&A opportunities for us at compelling valuations, and we anticipate additional disciplined and accretive acquisitions to accelerate our growth."

16:13 EST Celldex sees cash, equivalents sufficient to meet requirements through 2025

16:10 EST ADP announces $5B share repurchase program - The board of directors of ADP authorized the purchase of $5B of its common stock, Carlos Rodriguez, CEO, announced. This authorization replaces in its entirety the previous 2019 authorization to purchase $5B of its common stock. ADP had approximately 415M common shares outstanding as of October 28.

16:03 EST Kimco Realty acquires Long Island open-air grocery anchored portfolio - Kimco Realty (KIM) announced it acquired a private, multi-generationally-owned portfolio of eight Long Island, NY shopping centers for $375.8M. The acquisition was funded by the issuance of a combination of cash and redeemable units and the assumption of $88.8M of 4.1% mortgage debt with a remaining term of approximately six years. As of September 30, 2022, the company had $123.5M in cash and cash equivalents on its balance sheet and subsequently received approximately $301.1M of proceeds from the sale of 11.5 million shares of its Albertsons (ACI) common shares.

16:00 EST East Stone Acquisition Corp trading resumes

15:35 EST Vermilion Energy expects year-end 2022 debt to exceed previous target - Vermilion Energy stated: "With the potential funding of a windfall tax in Q4 2022 and a weaker Canadian dollar relative to the US dollar, we expect our year-end 2022 debt will exceed our previous target of $1.2 billion, however we anticipate we will remain below our leverage target. Following the EU approval of the windfall tax, we elected to suspend share repurchases under our NCIB for Q4 2022 as we continue to prioritize financial discipline and assess the impact of the windfall tax on our debt targets. We will evaluate the reinstatement of share repurchases under our NCIB once we have more clarity on the amount of windfall tax to be incurred in 2022 and the potential impact on 2023. Closing of the Corrib acquisition is nearing the final stages, and we now anticipate the acquisition to close in Q1 2023 due to administrative delays. As previously noted, all free cash flow generated by the acquired interest in Corrib from January 1, 2022 until close will accrue to Vermilion and be netted off the final purchase price. Our 2022 capital budget of $550 million and annual production guidance of 86,000 to 88,000 boe/d remain unchanged, however, we expect annual production to be at the lower end of this range as a result of fire-related downtime in France and delayed onstream timing of the Australia and United States wells. We plan to announce our 2023 budget in early January as we take additional time to assess the impact of the windfall tax, work with regulators in Europe to facilitate additional drilling, and confirm timing of the Corrib acquisition close. We will remain disciplined in 2023 as we continue to focus on debt reduction. At this time, we anticipate a capital budget similar to 2022 investment levels, with potentially a greater proportion allocated to European gas. We have the ability and desire to drill more wells in Europe, and, if ongoing discussions with regulators are productive, we will look to allocate additional capital to the region in 2023."

14:36 EST DraftKings lower after California voters reject sports betting measures - Shares of DraftKings (DKNG) are down 90c, or 7%, to $11.65 in Wednesday afternoon trading after voters in California shot down two propositions to legalize sports betting in the state. Proposition 26, which would have legalized sports betting at tribal casinos, and Proposition 27, which would have more broadly legalized online and mobile sports betting, were both voted down. The latter was put on the ballot by sports betting companies such as DraftKings and Flutter Entertainment's (PDYPY) FanDuel and opposed by Native American tribes.

13:54 EST Silvergate says can borrow from Federal Home Loan Bank, Federal Reserve if needs - Silvergate Capital issued the following statements regarding recent digital asset market volatility: "As a prudentially regulated bank, we manage our balance sheet to provide liquidity for our clients while maintaining a strong capital position in excess of the well-capitalized status required by federal banking regulations. We are a key infrastructure provider with an established track record, which gives our customers the confidence they need during times like these. In addition to our securities available-for-sale portfolio, which amounted to $8.3 billion at September 30, 2022, as a federally regulated banking institution, we have the ability to borrow from the Federal Home Loan Bank and the Federal Reserve Bank, further strengthening our liquidity position," said Alan Lane, CEO of Silvergate. "When our customers want to take advantage of trading opportunities at over 100 different exchanges that bank with Silvergate, the SEN facilitates these fund flows in near real-time, 24/7," said Ben Reynolds, President of Silvergate. "Silvergate also provides select, underwritten clients with access to bitcoin collateralized loans known as SEN Leverage. To date, these loans have continued to perform as expected with zero losses and zero forced liquidations," the company added.

13:30 EST Neptune Wellness announces completion of divestiture of cannabis assets - Neptune Wellness Solutions announced that is has completed the divestiture of its cannabis business which includes the cannabis plant in Sherbrooke, Quebec, the Mood Ring and PanHash brands, and related assets. Ray Silcock, CFO of Neptune, said, "We are pleased to complete the divestiture of our cannabis business, a critical milestone in executing upon our strategy to become a leading CPG company. The sale of the cannabis assets will allow us to realize significant cost savings and operational streamlining from redirected resources towards our simplified corporate structure, as we focus on Sprout as the key growth driver for Neptune going forward."

13:18 EST Occidental says it received strong interest in carbon capture - Says direct air capture plant to cost $1.1B, previous view $800M. Says "pleased" to have completed near-term debt retirement goal. Says has secured 260,000 acres to sequester carbon dioxide. Says production has increased steadily each quarter this year.

13:06 EST Verint Customer Engagement Platform to integrate with Zoom Contact Center - Verint (VRNT) and Zoom Video (ZM) announced an expanded partnership to help organizations deliver exceptional customer experiences across the enterprise through the additional integration of the Verint Customer Engagement Platform with Zoom Contact Center. Verint and Zoom have a shared vision for the future of customer experience by helping organizations close the Engagement Capacity Gap, the chasm between what organizations know they need to do to meet rising customer expectations and the resources they have to do it. Verint Data Management solutions are integrated with Zoom Phone and Zoom Meetings to help businesses capture, archive, analyze, ensure compliance, and retrieve interactions. The expanded partnership complements this platform-to-platform approach by connecting the Verint Platform to Zoom's rich set of Contact Center APIs to deliver workforce engagement.

12:46 EST HII unit wins U.S. Air Force $70M task order contract - HII's Mission Technologies division was awarded a $70M task order contract by the U.S. Air Force to perform technical analysis and recommend enhancements for the Air Force Research Laboratory. HII's research and analysis will be leveraged by the Air Force to support the Department of Defense's artificial intelligence/machine learning and cyber modernization priorities, the company said in a statement. HII will provide strategic planning; capabilities definition; system engineering; data analytics and visualization; modeling, simulation and analysis; and cloud technologies and cross domain solutions.

12:04 EST Immunome presents preclinical data on IMM20059 - Immunome announced that it is presenting a poster at the Society for Immunotherapy of Cancer's 37th Annual Meeting in Boston, Massachusetts highlighting the Company's preclinical data of IMM20059, a novel anti-epsin 1 antibody. Lack of response and immunoresistance to checkpoint inhibitors is a well-known challenge in cancer treatment. While the epsin-1 protein is known to be upregulated in a variety of tumor types, it can also be ectopically expressed on the tumor cell surface, as demonstrated in Immunome's poster, offering a new approach to cancer therapy. Insights into the role of epsin-1 as a potential target for cancer is evolving, but research by others1 also suggests targeting EPN1 has the potential to inhibt tumor growth. The findings presented by Immunome at SITC further suggest that combining an EPN1-targeting antibody, like IMM20059, with checkpoint inhibitor treatment could reactivate or increase immune response to the tumor. The poster presentation, IMM20059, a novel anti-EPN1 antibody, in combination with atezolizumab significantly enhances tumor regression in the B16.F10 syngeneic melanoma model compared to anti-PD-L1 monotherapy, highlights novel discoveries related to combinatorial activity between existing immune checkpoint inhibitors and the novel tumor target epsin 1. Immunome's preclinical research of IMM20059 in this poster demonstrated that: EPN1 is upregulated in multiple cancers and is ectopically expressed on tumor cell surfaces. IMM20059 binds with high affinity to both purified EPN1 protein and to the surface of B16.F10 melanoma tumor cells. In the combination treatment of IMM20059 and anti-PD-L1 atezolizumab, significant tumor regression was induced compared to IMM20059 or atezolizumab treatment alone, suggesting a combinatorial effect between the two anti-tumoral pathways. Combination treatment enhanced the production of intratumoral chemokines, MIP-1a, MIP-1b, and RANTES.

12:00 EST Wolverine World Wide falls -27.3% - Wolverine World Wide is down -27.3%, or -$4.93 to $13.12.

12:00 EST Emergent BioSolutions falls -33.9% - Emergent BioSolutions is down -33.9%, or -$6.69 to $13.04.

12:00 EST Quotient Technology rises 22.4% - Quotient Technology is up 22.4%, or 59c to $3.22.

11:43 EST Rail carriers to extend 'cooling off period' in talks to at least December 4 - The National Carriers' Conference Committee, or NCCC, which represents the nation's freight rail carriers in national collective bargaining, issued the following statement: "The NCCC and the Brotherhood of Maintenance of Way Employees Division of the International Brotherhood of Teamsters -BMWED - have agreed that the current cooling off period, which had been set to expire on November 19, will be extended until at least December 4 and is subject to further extension to maintain alignment, if necessary, with other labor organizations. This extension eliminates the threat of a near-term freight rail service disruption. The railroads will remain engaged with BMWED throughout the extended cooling off period and will continue to seek an agreement based on the framework recommended by Presidential Emergency Board 250. Agreements based on the PEB's recommendations were endorsed by President Biden as a 'win for tens of thousands of rail workers' and have been ratified by the members of seven other unions. Three unions have open ratification votes, and the cooling off period extension announced today will allow the members of these unions to complete their voting without disruption from the threat of a strike." Publicly traded companies in the rail carrier space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC) and Union Pacific (UNP). Reference Link

11:32 EST Occidental Petroleum sees Q4 oil & gas production 1,200-1,260 MBoed - Sees Q4 oxychem pre-tax income roughly $425M. Sees Q4 exploration expense about $115M. Guidance takne from Q3 earnings call presentation slides.

11:28 EST Redfin sinks 9% to $3.38 after shutting down house-flipping business

10:45 EST Cinedigm reaches new distribution agreement with Samsung - Cinedigm Corp. (CIDM) announced that it has reached a new distribution agreement with Samsung (SSNLF) that expands the reach of Cinedigm's flagship streaming service Cineverse to Samsung Smart TV users via the app store.

10:30 EST Guided Therapeutics says trial for Chinese marketing approval back on track - Guided Therapeutics announced that the clinical trial for Chinese regulatory is back on track after experiencing delays due to Covid-19 lockdowns and is expected to be completed and filed with the Chinese National Medical Products Administration during the first half of 2023. According to Guided Therapeutics Chinese partner, Shandong Yaohua Medical Instrument Corporation, the results so far indicate that LuViva meets or exceeds the success criteria as described in the current study protocol and has been demonstrated to be safe for use on nearly 200 women tested thus far in China. Hospitals participating in the study include Qilu Hospital of Shandong University, Fudan University Hospital and Peking University People's Hospital.

10:10 EST Merrimack surges after partner says Onivyde met primary endpoint in cancer trial - Merrimack Pharmaceuticals (MACK) shares are surging after the company announced earlier that partner Ipsen (IPSEY) issued a press release today reporting its primary analysis of the results of its Phase III NAPOLI 3 trial of Onivyde plus 5 fluorouracil/leucovorin and oxaliplatin, or the "NALIRIFOX regimen," as a treatment of first line metastatic pancreatic ductal adenocarcinoma, or mPDAC. The Ipsen press release indicates that the trial "met its primary endpoint demonstrating clinically meaningful and statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine in 770 previously untreated patients with metastatic pancreatic ductal adenocarcinoma and key secondary efficacy outcome of progression-free survival also showed significant improvement over the comparator arm. The safety profile of Onivyde in the NAPOLI 3 trial was consistent with those observed in the previous phase I/II mPDAC study," Merrimack announced. Ipsen indicated in its update that it intends to file a supplemental New Drug Application with the U.S. Food and Drug Administration for Onivyde in combination with oxaliplatin plus 5- fluorouracil/leucovorin for the treatment of patients with previously untreated mPDAC following the Fast Track Designation granted in 2020. "We are encouraged by these results which indicate progress toward a potential future milestone payment from Ipsen. We congratulate the Ipsen team and look forward to continuing to await further public announcements from Ipsen regarding progress with this important program," said Gary Crocker, Chairman and CEO of Merrimack Pharmaceuticals. In early trading, Merrimack shares have advanced $7.90, or 198%, to $11.90.

10:02 EST BAE Systems awarded $17M contract to develop video game experience - The Air Force Research Laboratory awarded BAE Systems a $17M contract to introduce artificial intelligence into an interactive game environment to revolutionize air operations planning for contested environments. As part of the Fight Tonight program, the company will provide air operations planners with the tools they need to dramatically accelerate the process of planning complex air attack operations. Under the terms of the Technical Area 2, Plan Gaming and Outcome Analysis contract, BAE Systems' FAST Lab research and development organization, along with subcontractors Uncharted Software and Kestrel Institute, will develop a solution to rapidly generate and review multiple plans and select the most robust.

10:00 EST Wolverine World Wide falls -20.2% - Wolverine World Wide is down -20.2%, or -$3.64 to $14.41.

10:00 EST Life Time Group rises 17.5% - Life Time Group is up 17.5%, or $1.71 to $11.50.

10:00 EST LiveRamp rises 19.1% - LiveRamp is up 19.1%, or $2.99 to $18.61.

09:47 EST Custom Truck One Source falls -13.5% - Custom Truck One Source is down -13.5%, or -92c to $5.89.

09:47 EST Chart Industries falls -17.3% - Chart Industries is down -17.3%, or -$41.47 to $198.00.

09:47 EST Fiverr rises 11.8% - Fiverr is up 11.8%, or $3.35 to $31.77.

09:47 EST Meihua International Medical Tech Co Ltd trading resumes

09:43 EST CarGurus trading resumes

09:42 EST Meihua International Medical Tech Co Ltd trading halted, volatility trading pause

09:40 EST Upstart Holdings trading halted, volatility trading pause

09:37 EST Natera trading halted, volatility trading pause

09:30 EST CarGurus trading halted, volatility trading pause

09:29 EST WisdomTree reports organic growth accelerated 14% YTD through OCtober - WisdomTree's organic growth accelerated to nearly 14% year-to-date through October, up from the 12% annualized year-to-date pace at the end of September. Nearly $2 billion of inflows in October extends monthly firm-wide net inflow streak to 14 consecutive months and 21 of the prior 24 months. U.S. Equity products have generated net inflows in 28 of the prior 29 months, including $266 million in October 2022, a 15% organic growth rate in the period. Filed for nine additional blockchain-enabled funds, including both fixed income and equity focused strategies.

09:21 EST Novavax' Nuvaxovid authorized in U.K. for use as booster in adults - Novavax announced that the Medicines and Healthcare products Regulatory Agency in the U.K. has expanded the conditional marketing authorization for Nuvaxovid COVID-19 vaccine as a homologous and heterologous booster dose after the primary series of Nuvaxovid or of an mRNA or adenoviral vector vaccine for active immunization to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 in adults aged 18 and older.

09:16 EST Innodata wins two Synodex platform deals - Innodata announced that it has won Synodex platform deals with two new customers - each a Fortune 500 diversified financial services company with over $200 billion in assets. Innodata estimates the two engagements collectively at $1.1 million per year of ongoing annual revenue. One of the engagements is due to kick off this week and the other is anticipated to begin in Q1 of 2023.

09:15 EST SharpLink Gaming appoints Dave Abbott as CTO - SharpLink Gaming (SBET) announced that Dave Abbott, former Managing Director of U.S. Sports Media at Sportradar (SRAD), has been appointed as SharpLink's new Chief Technology Officer, effectively immediately.

09:12 EST Aptevo, Alligator announces publication on ALG.APV-527 preclinical data - Alligator Bioscience and Aptevo Therapeutics announced the publication of a peer-reviewed article highlighting preclinical data that demonstrates a positive safety and anti-tumor activity profile in both in vitro and in vivo studies for ALG.APV-527, a novel second generation 4-1BB agonistic bispecific antibody that is designed to stimulate 4-1BB function only when co-engaged with the tumor-associated antigen 5T4. The publication in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research, includes data provided in the companies' investigational new drug application to the US Food and Drug Administration supporting the advancement of ALG.APV-527 into the clinic for evaluation in the treatment of multiple solid tumor types. The article, entitled "The bispecific tumor antigen-conditional 4-1BB x 5T4 agonist, ALG.APV-527, mediates strong T cell activation and potent anti-tumor activity in preclinical studies", demonstrates how the design, epitope, and molecular properties of ALG.APV-527 translate into a potentially safe and potent anti-cancer therapeutic both in vitro and in vivo for the treatment of multiple solid tumor types. The preclinical functional data presented demonstrate that ALG.APV-527 has the potential to activate key immune cell populations such as T cells and NK cells within the tumor microenvironment. Of particular importance is the favorable safety profile, where the preclinical data demonstrates a potentially wider therapeutic window for ALG.APV-527 compared to first generation 4-1BB agonists.

09:09 EST Euronet Worldwide announces partnership with Africa Electronic Trade Group - Euronet Worldwide announced a partnership with the Africa Electronic Trade Group to build a multi-channel, real-time cross-border payments gateway for the African continent. The Euronet-powered payments switch will serve as the financial foundation for an initial 44 of the 54 possible countries in the African Continental Free Trade Area that connects a population of about 1.4 billion people with a combined GDP of approximately US$3.4 trillion. Utilizing Euronet's Ren payments technology, the switch will enable central banks, regional processors, financial institutions, regional mobile wallets and small and medium enterprises to easily make transactions with each other in real time and bring many new banking benefits and capabilities to African citizens. "For almost 30 years now, we have been diligent in bringing financial inclusion to people wherever they are through our core values of innovation and hard work," said Michael Brown, President and CEO of Euronet. "This project, where our Ren payments technology will serve as the real-time payments switch across the African continent, provides one of the biggest milestones in this journey. Our past experience and successful track record in re-wiring the global financial infrastructure to better serve businesses and consumers ensures we have the expertise to deliver results for this crucial project and increase the financial participation of African citizens for generations to come."

09:07 EST Big Lots announces new Chief Merchandising, Chief Marketing Officer - Big Lots announced the appointment of two new members of its leadership team. Off-price retail industry veteran Margarita Giannantonio has been named Chief Merchandising Officer and retail industry brand and performance marketing leader John Alpaugh has joined Big Lots as Chief Marketing Officer. Giannantonio spent the last decade with TJX, which includes off-price retail brands like HomeGoods, HomeSense, T.J. Maxx and Marshalls. She was most recently Senior Vice President and General Merchandise Manager of TJX Canada, where she led teams responsible for merchandise strategy and financial plans. Building on his successes as a business planner for IBM, John Alpaugh spent six years in Frankfurt, Germany, with Procter and Gamble in brand management before holding various leadership roles with PetSmart.

09:06 EST STMicroelectronics says ST54K IC selected for Google Pixel 7 smartphone - STMicroelectronics has revealed that its ST54K IC is handling control and security for contactless NFC communication in the newly launched Google Pixel 7 smartphone. Chosen by Google's designers, ST's device combines NFC control and a certified Secure Element in a single chip that saves space and simplifies handset design. Containing proprietary technologies that enhance NFC contactless sensitivity, the ST54K was selected to ensure the most reliable connectivity, deliver excellent contactless user experiences, and ensure the highest contactless transaction security.

09:05 EST HubSpot announces Alyssa Harvey Dawson as new Chief Legal Officer - HubSpot announced that Alyssa Harvey Dawson has joined the company as Chief Legal Officer, CLO. Harvey Dawson joins the company from Gusto, Inc., where she also served as CLO, and will oversee HubSpot's legal and compliance teams. "We are incredibly fortunate to be welcoming Alyssa as our new Chief Legal Officer," said Yamini Rangan, CEO of HubSpot. "During the interview process, it was clear that Alyssa's core values are strategically aligned with those of HubSpot. A humble and empathetic leader, Alyssa demonstrates that she is mission-driven and customer-focused, two qualities that are incredibly important as HubSpot continues to scale. I'm thrilled to have Alyssa on the team and look forward to learning from and working with her."

09:04 EST Uber, Grocery Outlet expand partnership - Uber Technologies (UBER) and Grocery Outlet Holding Corp (GO) announced the expansion of their partnership, extending on-demand and scheduled grocery delivery across the country. Starting immediately, Grocery Outlet locations across New Jersey, Maryland and Pennsylvania will come online, joining storefronts in California, Oregon, and Washington for a total of 386 across the country including Los Angeles, San Francisco, San Diego, Philadelphia, Seattle, Sacramento, Portland and more.

09:03 EST MICT scheduled to complete acquisition of Tingo prior to November 30 - MICT, Inc. (MICT) and Tingo, Inc. (TMNA) announced the filing of Tingo's Definitive Information Statement regarding the merger of Tingo Mobile PLC, Tingo's sole operating subsidiary with MICT. As more than 77% of Tingo's total voting power approved the Merger, MICT and Tingo have now scheduled a closing date of the Merger for November 30, 2022. Upon completion of the merger, MICT will own 100% of the operating business and assets of Tingo Mobile, in return for which MICT is issuing 19.9% of its common stock to Tingo, together with Series A Preferred Stock and Series B Preferred Stock, each of which are convertible into shares of MICT's common stock upon certain conditions being satisfied. As a wholly owned subsidiary, 100% of the revenues, expenses and net income of Tingo Mobile will be consolidated into MICT's group accounts, making MICT significantly more profitable from the Closing Date.

09:02 EST Nektar announces publication of preclinical data on NKTR-255 in lymphoma - Nektar announced the publication of preclinical data in Blood Advances, the open-access journal of the American Society of Hematology, highlighting the effects of NKTR-255, a novel polymer-conjugated human IL-15, on the efficacy of human CD19 CAR-T cells in a xenogeneic lymphoma model and on CD8+ T effector cell and natural killer cell proliferation in non-human primates. "The findings published today reinforce the foundational rationale behind the clinical development program we're pursuing of NKTR-255 enhancing CAR-T cell therapies," said Jonathan Zalevsky, Ph.D., Chief Research & Development Officer at Nektar. "We are looking forward to progressing our research in combination with cell therapies and are excited to launch our Phase 2/3 clinical trial of NKTR-255 following approved CAR-T cell therapies in patients with relapsed or refractory diffuse large B-cell Lymphoma." The data from this publication demonstrate that NKTR-255 enhanced in vivo proliferation and accumulation of T and NK cells in non-human primates, and demonstrated enhanced in vivo antitumor efficacy of human CD19 CAR-T in lymphoma-bearing immunodeficient mice.

09:01 EST SharpLink Gaming receives noncompliance notification from Nasdaq - SharpLink Gaming announced that SharpLink has received a letter from Nasdaq Listing Qualifications on November 4 indicating that the company is no longer in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550, which requires listed securities to maintain a minimum bid price of $1.00 per share.

08:55 EST Bigg Digital Assets' Netcoins announces relaunch of Netcoin Pay - BIGG Digital Assets (BBKCF) and Blockchain Intelligence Group announces the re-launch of Netcoins Pay in partnership with Koho Financial and Mastercard (MA). Netcoins, through its partnership with KOHO Financial, is re-launching its Netcoins Pay proposition with Mastercard in Canada. Netcoins Pay users will continue to accumulate Bitcoin rewards as a form of 'Cash Back' based on their everyday spending. Mastercard has taken strides to support the crypto industry and will be working closely with Netcoins to ensure that we are providing our Netcoins Pay users with the same great experiences in Canada that we are seeing with global leaders. The new Netcoins Pay card will have an updated look to match the updated Netcoins Brand and will stand out in users' wallets in both physical and digital forms. Users can migrate to receive their new Mastercard. A dedicated marketing campaign and competition will follow on social media.

08:55 EST Veru trading halted, news pending

08:54 EST D.R. Horton: Goal is for FY23 revenue to be 'slightly higher' than FY22 - Says current model may see FY23 revenue potentially down from FY22 by a mid-teens percentage. Consensus is $29.99B.

08:54 EST Royalty Pharma agrees to acquire royalty interest in olpasiran from Arrowhead - Royalty Pharma (RPRX) and Arrowhead (ARWR) announced that Royalty Pharma has acquired a royalty interest in Amgen's (AMGN) olpasiran from Arrowhead Pharmaceuticals for $250M in cash upfront plus up to $160M in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones. "We are delighted to partner with Arrowhead, a leader in RNA interference therapeutics, to help them achieve their strategic objectives and fund their attractive pipeline," said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer. "Cardiovascular disease remains the most common cause of death worldwide despite certain treatment advances, and new therapeutic targets are greatly needed. Olpasiran is a promising late-stage treatment approach with the potential to lower lipoprotein, and this agreement is consistent with our strategy of acquiring innovative therapies in areas of high unmet patient need."

08:52 EST AirSculpt Technologies announces completion of debt refinancing - AirSculpt Technologies announced that it has entered into a new credit agreement with several new lenders. The new credit agreement consists of an $85.0 million aggregate principal amount of term loans and a revolving loan facility in an aggregate principal amount of up to $5.0 million. The proceeds were used to pay off the Company's existing $83.6 million outstanding principal balance under its existing credit facility coming due on October 28, 2023. The new credit agreement will mature in five years on November 7, 2027. The Company expects cash interest savings of approximately $2 million annually and there are no prepayment penalties under the new agreement.

08:51 EST Teknova announces new WFI quality water product line for bioprocessing market - Alpha Teknova announced a new WFI Quality Water product line for the bioprocessing market now available through the company's online catalog, or by email or phone order. 20L and 200L single use bags are available and ready to ship the next day after order placement. "In response to increasing customer demand and a shortage of readily available WFI grade products, we are pleased to now offer our WFI Quality Water line as a new multi-use option in our growing catalog portfolio to alleviate bottlenecks in bioprocessing workflows," said Stephen Gunstream, President and Chief Executive Officer of Teknova. "As a trusted partner to the bioprocessing sector, Teknova's mission is to make solutions possible. We continue to develop new, high-quality products to meet rapidly changing customer needs with an emphasis on quick turnaround times. We look forward to working with customers to create integrated solutions to increase workflow efficiency in the development of novel therapies."

08:50 EST Altamira Therapeutics regains compliance with NASDAQ minimum bid requirement - Altamira Therapeutics announced that it has regained compliance with the Nasdaq listing requirements. On November 08, 2022 the Company received a letter from Nasdaq stating that because the Company's shares had a closing bid price at or above $1.00 per share for a minimum of ten consecutive business days, the Company's stock had regained compliance with the Minimum Bid Price Requirement for continued listing on Nasdaq, and that the matter is now closed.

08:48 EST Glencore subscribes for 29.2M ordinary hares of Horizonte Minerals - On November 8, 2022, Glencore International, completed the subscription for 29,208,892 ordinary shares in the capital of Horizonte Minerals PLC at an issue price of GBP 0.905 per new Ordinary Share or C$1.38 per share, for an aggregate subscription price of US$30,000,000 or C$40,551,000. The Transaction was completed as part of HZM's private placing of 48,681,487 new Ordinary Shares to certain existing and new institutional investors and others and allotment of an aggregate of 29,264,140 Ordinary Shares to Glencore and certain related parties of HZM. Immediately prior to completing the Transaction, Glencore owned and exercised control over 18,662,914 Ordinary Shares, representing approximately 9.80% of the issued and outstanding Ordinary Shares at such time. After giving effect to the Transaction, Glencore now owns and controls a total of 47,871,806 Ordinary Shares, representing approximately 17.84% of the issued and outstanding Ordinary Shares. Glencore's decision to complete the Transaction was made in the context of its overall investment purposes. Glencore will continue to review its investment alternatives from time to time and may determine to increase or decrease its equity ownership in HZM through the acquisition or sale of additional outstanding common shares or other securities of HZM through open market or privately negotiated transactions in accordance with applicable securities laws.

08:46 EST Quisitive Technology selected by Visa to modernize payment processing for PayiQ - Quisitive Technology Solutions (QUISF) announced that it has entered into a partnership with Cybersource, a Visa (V) solution, to directly access VisaNet and expand the payment acceptance model for PayiQ. By working with Visa, PayiQ opens a new distribution channel of Independent Software Vendors to connect directly to Visa, allowing acquiring banks to use Visa's network and processing without the need for third-party payment processors. Created to bring a new level of innovation to technology companies and software vendors, this partnership combines Cybersource's acquiring solutions with PayiQ's suite of automated management tools and settlement management to deliver integrated payments. "We are excited to be able to partner with Cybersource to deliver a new, cloud-enabled processing solution that transforms what has been a host of slow, manual management processes to a 21st century level of automation," says Jana Schmidt, President of Quisitive's Global Payments Solutions. "This infrastructure is just the start of a collaboration that will continue to support innovative products and services while driving new verticals, new geographies, and new technologies."

08:45 EST Vicinity Motor secures power solution fo facility in Ferndale, Washington - Vicinity Motor provided a corporate update on the construction of the Company's new manufacturing facility in Ferndale, Washington. As previously announced, the property is located near the Company's Aldergrove, British Columbia Canadian Headquarters with easy access to port, rail and truck shipping and receiving facilities. Operations at the facility will include vehicle assembly and upfitting, "Buy America" compliant assembly, pre-delivery inspections, research and development, as well as general technical work and servicing."We are pleased to report the expected procurement and installation of a power solution for our Ferndale facility by year-end - enabling us to secure our certificate of occupancy," said William Trainer, Chief Executive Officer of Vicinity Motor Corp. "The Ferndale facility is exciting as it was built to accommodate both buses and trucks, with a capacity of up to 1,000 buses per year or up to 10,000 trucks at the projected maximum production rate. We are currently in the process of certifying our 4.2 acre campus as a Free Trade Zone, allowing our vehicles to be easily exported to Canada.

08:43 EST D.R. Horton: October cancellations remained elevated

08:42 EST DriveItAway partners with DigiSure - DriveItAway Holdings announced its partnership with DigiSure, the only Protection-as-a-Service platform providing screening, insurance management and claims handling. The DriveItAway platform was created for car dealers to enable all consumers, regardless of credit score or cash down payment, to drive and buy a vehicle tailored to the individual's choice. By design, it solves two of the biggest impediments for all buyers of EVs, namely, the higher upfront cost which is spread out while driving on a DriveItAway subscription, and the question of suitability or range anxiety. The DriveItAway program allows for an unlimited "test drive" with the option to purchase available at any time with money paid in going towards the purchase price. The partnership gives DriveItAway the confidence to add subscribers without increasing the risk of theft or other losses. DigiSure's comprehensive screening process checks for identity & fraud, criminal history, insurance risk, and a subscriber's ability to meet their financial commitments.

08:41 EST Vivid Seats announces Make-A-Wish partnership - Vivid Seats announced it is partnering with Make-A-Wish to bring awareness to the power and impact of a wish for children and families Vivid Seats' mission is to empower every fan to get to the live events that shape their most vivid moments and memories. Through its charitable foundation Vivid Cheers, Vivid Seats is furthering that mission and pledging $250,000 to support the granting of wishes through live event experiences. Throughout its Make-A-Wish partnership, Vivid Seats is committed to helping to make wishes come true and bring added strength and courage to children battling critical illness through the power of a wish.

08:40 EST D.R. Horton: Net sales orders in October below prior-year levels - Comments taken from Q4 earnings conference call.

08:38 EST PetVivo to exhibit SPRYNG at AAEP conference - PetVivo Holdings announced it will be exhibiting at the American Association Equine Practitioners conference to be held November 19th to November 22nd, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. PetVivo intends to exhibit its lead product, SPRYNG with OsteoCushion Technology, a medical device injection of sterilized, extra-cellular matrix microparticles that are lubricious and spongy used in the treatment of lameness and other joint related afflictions, such as osteoarthritis. The AAEP is the largest veterinary equine conference that services the United States, and normally plays host to more than 5,000 participants including many of the top industry professionals.

08:37 EST Roblox falls 15% to $33.10 after Q3 results miss estimates

08:36 EST WisdomTree announces listing transfer to NYSE - WisdomTree announced that it will ring the opening bell at the New York Stock Exchange, celebrating the transfer of its common stock listing to the NYSE under the new ticker symbol "WT" and its new company name, WisdomTree. Jonathan Steinberg, WisdomTree Founder and CEO, said, "I founded WisdomTree over 15 years ago with the goal of offering investors a well-diversified suite of world-class exchange-traded products that deliver better results with less volatility. Today, I'm proud that our business is delivering robust organic growth and that we have significant opportunities ahead in both the exchange-traded products, models and advisor solutions business as well as by being an early mover in digital assets and blockchain-enabled financial services. Ringing the opening bell at the NYSE celebrates the natural evolution of our business, grounded in our history of innovation while looking ahead to deliver more breadth, balance and consistency in our organic growth, that will continue to benefit investors in our products and our stockholders."

08:35 EST Rigetti Computing announces update to CEO leadership transition - Rigetti Computing announced that the Company's Founder, Dr. Chad Rigetti, has provided to the Company his intention to tender resignation from his positions as the Company's President, Chief Executive Officer and Director on the Company's Board of Directors, with an anticipated effective date of December 15, 2022. As previously announced, the Company is conducting a search for Dr. Rigetti's successor. In the event the Company is unable to identify and appoint a successor before Dr. Rigetti's resignation date, it is anticipated that Rick Danis, the Company's General Counsel and Corporate Secretary, will serve as interim President and Chief Executive Officer as of such date until a successor to Dr. Rigetti has been appointed.

08:34 EST Surgalign announces corporate restructuring program - Surgalign announced that its Board of Directors has approved a corporate restructuring plan intended to help drive growth in the most valuable and profitable parts of the Company's business. As part of the plan approved on November 8, 2022, Surgalign intends to continue its brand and product rationalization programs, which are expected to result in a greater focus on new products brought to market over the past year and core hardware products that hold the greatest growth prospects. Throughout the fourth quarter of 2022 and into early 2023, the Company intends to discontinue some of its lower performing SKUs, which will enable the redeployment of resources across research and development and support the commercialization of products that align with the go-forward business strategy. Additionally, as part of its focus to improve operational efficiencies, the Company intends to continue ongoing efforts, as well as initiate several new programs designed to streamline and optimize resources and lower future working capital requirements. As a result of the restructuring programs and initiatives planned, the Company expects an estimated cash savings of approximately $30.0 to $35.0 million compared to 2022. The Company also disclosed that its Board of Directors has approved the exploration of further restructuring initiatives, which include but are not limited to, the potential paring down, selling or exiting certain aspects of its business, both domestically and abroad. To achieve these savings, the Company expects to incur approximately $3.0 - $3.5 million in employee-related severance costs and $2.5 - $3.5 million in other exit and disposal costs in the fourth quarter of 2022 and first quarter of 2023 for a total estimated restructuring cost of approximately $5.5 - $7.0 million. Estimated cash savings are expected to be realized throughout 2023 and programs are anticipated to begin late in the fourth quarter of 2022 and be substantially complete in the first half of 2023.

08:33 EST Aleafia Health announces winddown of Grimsby greenhouse - In Q3 FY2023, the Company is enacting further cost savings initiatives with the winddown of its Grimsby greenhouse, representing an annualized net savings of approximately $4.1 million. The Company is focused on continuing to build the brand awareness of its everyday value brand, Divvy, by supplying its consumers with innovative sought-after cultivation strains from the best sources of flower supply, whether that be internally grown or procured from other third-party growers. The Company will commence the process of winding down operations, effective November 2022, impacting 41 employees. "Over the last four quarters the Company has experienced consistent whole flower stock outs as the scale of the Grimsby greenhouse was outstripped by consumer demand for our products. We have mitigated this issue by onboarding strategic partners to supply our ongoing requirements," said Symmes. "We want to sincerely thank our valued employees at the Grimsby greenhouse for their many contributions over the years, particularly in the launch of Divvy and transformation of our business to a branded cannabis provider. Aleafia today is delivering on its core commitments across all four pillars of our strategic growth plan," said Symmes. "With innovative and sought-after formats directed strategically toward high-margin adult-use categories, it's an exciting time for the Company as we demonstrate that we can achieve our lofty goals. Our motivated team is creating the best branded cannabis company in the country, devoted to expanding our reach in the adult-use, medical and international markets with best-in-class branded products. We believe this is the first of many profitable quarters and will continue to execute on our long-term strategy to drive sustainable profitable growth for the Company and all its shareholders. Although we're not the biggest and we're not the first, we strive to build the best branded cannabis company with the aspiration of leading in Canada and globally."

08:30 EST Genetic announces publication of study on geneType ovarian cancer test - Genetic Technologies announces the publication of a validation study evaluating the performance of the geneType ovarian cancer test. This 10 year prospective cohort study utilizes data from more than 190,000 women and has been published in the prestigious European Journal of Cancer Prevention. The paper titled "A combined clinical and genetic model for predicting risk of ovarian cancer.". Publication highlights: GeneType Ovarian Cancer Risk Assessment Test significantly improves the identification of 10 year and lifetime risk in the general population of women who would normally be considered 'average risk'. Genetype for Ovarian Cancer is able to identify the top 20% of women who are: at over 40% increased 10-year risk and; over 50% increased full-lifetime compared to the general population. GeneType for Ovarian Cancer is similarly able to identify women who are at very low risk. Study references 10 year prospective cohort study utilizing data from approximately 190,000 women aged between 40 and 69 from the UK Biobank. Identification of high-risk women enables introduction of traditional and novel screening options and / or risk-reducing strategies to drive a significant improvement in patient outcomes.

08:29 EST aTyr Pharma announces publication of data from Phase 1b/2a study of efzofitimod - aTyr Pharma announced the publication in the journal CHEST of positive results from a Phase 1b/2a randomized, double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease. The study demonstrated that efzofitimod was safe and well-tolerated at all doses and exhibited a consistent dose response on key efficacy endpoints and improvements compared to placebo, including measures of steroid reduction, lung function, sarcoidosis symptom measures and inflammatory biomarkers. "The publication of this manuscript marks the first peer-reviewed publication of clinical data for efzofitimod in a major medical journal. These data indicate that efzofitimod is providing substantial benefit to patients - improving lung function and symptoms of cough, shortness of breath and fatigue - all while reducing their toxic steroid burden," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "EFZO-FIT(TM) is expected to be the largest interventional study for patients with sarcoidosis to date, and we believe efzofitimod is well positioned to be the first disease modifying therapy to market for patients with this debilitating disease."

08:27 EST Clever Leaves granted EU-GMP certification from Portuguese Health Authority - Clever Leaves announced that its facility in Portugal has been granted EU-GMP certification by the Portuguese Health Authority to manufacture dried cannabis flower as an active pharmaceutical ingredient and as finished product. The EU-GMP certification is required for the registration and marketing of medicinal cannabis products in Europe and represents an important step toward broadening Clever Leaves' ability to reach European patients with its own products. Andres Fajardo, Clever Leaves' CEO, stated, "Receiving this certification and completing the rigorous process is an honor and accomplishment for Clever Leaves, from the initial design of the installations, through the qualification and validation of all equipment and processes, to the integration of the new unit's quality procedures into the existing quality system of Clever Leaves Portugal. The fact that we were able to meet the highest of pharmaceutical standards in less than 10 months after completion of the new facility is a huge milestone for Clever Leaves and we could not be more proud of our team for their exemplary work."

08:26 EST Pipestone Energy modifies three-year production forecast - As a result of several technical, inflationary, and other economic factors discussed below, Pipestone is modifying its 3-year production forecast and target production plateau from approximately 55,000 boe/d to approximately 45,000 boe/d. Average annual production growth for 2022 2025 is now expected to be approximately 7 - 10%, versus approximately 16% previously. This reduced production growth rate will allow the Company to maximize free cash flow and returns to investors.

08:26 EST Xwell announces planned opening of five new XpresSpa locations in IST - XWELL continues its international expansion with the planned opening of five new XpresSpa locations in Istanbul International Airport, IST. Located in the city known as the crossroads of the world, Istanbul International Airport is one of the busiest airports in the world, serving 262 destinations. "As one of the world's highest-ranking airports, the new Istanbul International Airport is a great fit for the premium experiences offered by XpresSpa," said XWELL Chief Executive Officer Scott Milford. "The new, refreshed XpresSpa locations are perfect for international travelers looking for an oasis before boarding a flight. Our new spas provide travelers with the products and services to promote a healthy well-being. We are delighted to open these new XpresSpa locations as the expansion into Istanbul marks another key milestone in XWELL's transformation and growth." Two XpresSpa locations are currently open with one more scheduled to open on November 10. The remaining two locations are expected to open in December.

08:24 EST Fortress Transportation shareholders approve merger agreement - Fortress Transportation and Infrastructure Investors announced that its shareholders have voted to approve and adopt the previously announced merger agreement, dated August 12, 2022, by and among FTAI, FTAI Finance Holdco, which following the completion of the merger will be named FTAI Aviation, and FTAI Aviation Merger Sub. FTAI's public common shareholders will not need to take any action in connection with the merger. Pursuant to the merger, shares of FTAI will be exchanged automatically for shares of FTAI Aviation without any further action from the shareholders and FTAI will become a subsidiary of FTAI Aviation. Following the merger, the ordinary shares and preferred shares of FTAI Aviation are expected to continue to trade on Nasdaq under the existing ticker symbols "FTAI," "FTAIP," "FTAIO" and "FTAIN," respectively. The closing of the merger is anticipated to occur on November 10, 2022.

08:22 EST Aptevo, Alligator publish ALG.APV-527 preclinical data in AACR journal - Alligator Bioscience AB and Aptevo Therapeutics announced the publication of a peer-reviewed article highlighting preclinical data that demonstrates a positive safety and anti-tumor activity profile in both in vitro and in vivo studies for ALG.APV-527, a novel second generation 4-1BB agonistic bispecific antibody that is designed to stimulate 4-1BB function only when co-engaged with the tumor-associated antigen 5T4. The publication in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research, includes data provided in the companies' investigational new drug application to the US Food and Drug Administration supporting the advancement of ALG.APV-527 into the clinic for evaluation in the treatment of multiple solid tumor types.The article, entitled "The bispecific tumor antigen-conditional 4-1BB x 5T4 agonist, ALG.APV-527, mediates strong T cell activation and potent anti-tumor activity in preclinical studies", demonstrates how the design, epitope, and molecular properties of ALG.APV-527 translate into a potentially safe and potent anti-cancer therapeutic both in vitro and in vivo for the treatment of multiple solid tumor types. The preclinical functional data presented demonstrate that ALG.APV-527 has the potential to activate key immune cell populations such as T cells and NK cells within the tumor microenvironment. Of particular importance is the favorable safety profile, where the preclinical data demonstrates a potentially wider therapeutic window for ALG.APV-527 compared to first generation 4-1BB agonists.

08:21 EST Marathon Gold reports Q3 capex C$33.5M vs. C$14.7M last year - Matt Manson, President, and CEO commented: "The third quarter saw us complete a number of important milestones for the development of the Valentine Gold Project. In late August we announced a positive Decision Statement from the Minister of Environment and Climate Change Canada marking the completion of the federal EA process. Combined with the earlier release from our provincial EA in March, we have now successfully completed what has been over three years of environmental and social assessment for the Project at both levels of government. On September 1st, we announced a formal decision by the Company, to proceed with Project construction. The completion of our US$185 million project debt arrangements in March, and the recent $150 million equity financing, ensure we go into this process with a strong balance sheet and sufficient financial capacity to commit on equipment, contracts and people. Operating permits and authorizations have been received in a timely fashion, and subsequent to the quarter-end, we commenced our early works program at site. This has included temporary camp installation, pad construction, road and bridge upgrades, equipment delivery, and pre-stripping activities at the Leprechaun Deposit. The Valentine Gold Project is on track to become Atlantic Canada's largest gold mine: a long-lived open-pit project, with a large and high-grade Mineral Reserve, good logistics and infrastructure, and the support of the people and communities of central Newfoundland. Importantly, Valentine is also continuing to grow. In July we published a new Mineral Resource Estimate, which incorporated two years of drilling at the Berry Deposit and an RC drilling program at the Leprechaun and Marathon Deposits. The new estimate is the largest and best quality produced for the Project to date. The addition of Berry to our mine planning offers a positive on mine life and gold production profile, even as we manage the increased cost environment. An Updated Feasibility Study, which will bring these strands together in a 3-pit mine plan for the first time, is on track for completion in the fourth quarter. Above and beyond the scope of this updated mine plan, we continue to see additional positive results from our in-fill drilling at Berry, and our prospecting efforts are identifying new areas of future exploration potential."

08:19 EST Arena Minerals completes exploratory drill hole R-03 at SDLP Project - Arena Minerals announced it has completed exploratory drill hole R-03 on the Barreal II claim block, which forms part of the northernmost portion of the Sal de la Puna Project located in the Pastos Grandes basin within Salta province, Argentina. The rotary exploratory hole intersected two brine aquifers and was drilled down to a total depth of 620 metres below surface. The two brine aquifers consist of: 90 metres averaging 538 milligrams per litre lithium; 255 metres averaging 641 mg/l Li. Both discovered brine aquifers are predominantly composed of alluvial sands with minor halite. The lower aquifer commenced at a depth of 360 metres and intersected brines assaying up to 695 mg/l Li, representing the highest grade reported intercept in the Pastos Grandes basin. The aquifer remains open at depth as the drill hole was stopped at 620 metres in alluvial sands due to drill capabilities. William Randall, President & CEO of Arena, stated, "Our second exploration hole delivers our best drill results to date, opening the northern portion of our claim blocks to resource development. The grades, brine quality and aquifer material warrant further drilling to expand this brine resource to the north onto our larger La Relojera and Barreal III claims." The brine maintains the favourable high-quality geochemistry with an average magnesium to lithium ration of 5.5 and sulphate to lithium ration of 10.5, similar to those encountered throughout the Pastos Grandes basin.

08:18 EST Arrowhead sells royalty interest in olpasiran to Royalty Pharma for $250M+ - Arrowhead Pharmaceuticals (ARWR) and Royalty Pharma (RPRX) announced that Royalty Pharma has acquired a royalty interest in Amgen's (AMGN) olpasiran from Arrowhead for $250M in cash upfront plus up to $160M in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones. Olpasiran is a small interfering RNA, siRN. originally developed by Arrowhead using its proprietary Targeted RNAi Molecule, or TRiM , platform and licensed to Amgen in 2016. It is designed to lower levels of lipoprotein a genetically-determined independent risk factor for cardiovascular disease, and is entering a Phase 3 cardiovascular outcomes study to determine whether treatment with olpasiran can reduce the risk of cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of Lp. Phase 2 study results from the OCEAN -DOSE study were presented at the American Heart Association Scientific Sessions 2022, where olpasiran demonstrated a significant and sustained reduction in Lp(a) levels over 36 weeks. These data were simultaneously published in the New England Journal of Medicine on November 6, 2022. "We are pleased to reach this agreement with Royalty Pharma, which is recognized as a leader in funding innovation across life sciences," said Chris Anzalone, Ph.D., Arrowhead's President and Chief Executive Officer. "Olpasiran, which we developed and licensed to Amgen for further clinical development and commercialization, has the potential to benefit millions of patients worldwide by reducing the risk of cardiovascular disease. The early monetization of this potential royalty stream validates olpasiran's significant potential and enables us to continue to invest in our TRiM platform and our diverse and growing pipeline of RNAi therapeutic candidates."

08:17 EST Tilt Holdings enters manufacture, distribution agreement with Curaleaf - TILT Holdings announced Jupiter Research has entered into an exclusive five-year manufacture, supply and distribution agreement with Curaleaf International to bring the Jupiter manufactured Liquid Que vaporizer to new territories abroad, for use as a medical device with extracts developed by Curaleaf International, subject to obtaining regulatory approvals in the relevant territories. Introduced in 2020, the Liquid Que vaporizer is the first independent pod system to be manufactured by Jupiter Research. Featuring a snap-in pod cartridge, magnetic connection, and rechargeable power supply, the Liquid Que's cutting-edge design preserves the integrity of high-viscosity extracts at every stage. Jupiter Research will be Curaleaf International's exclusive supplier of all vaporizer hardware, cartridges, and related accessories including the Liquid Que, for use with liquid medical cannabis products, bringing it initially to the United Kingdom and European Union, with other territories such as Switzerland, Norway, Australia, Israel, and the United Arab Emirates to follow. Curaleaf International will in turn develop each market, coordinate approval of the formulations and extracts in each territory per local regulations and distribute the approved Liquid Que device in these markets exclusively. The Liquid Que is expected to reach the UK beginning in late 2023.

08:14 EST American Noble Gas provides update on investments, expansion into helium - American Noble Gas announces that it has become one of the few United States publicly traded companies that is actually producing and selling helium gas from its Peyton 21-1 well and further confirmed that its initial production is generating positive cash-flow from its Hugoton Gas Field operations. The Company also provided operating results from its GMDOC, LLC investment that has exceeded its expectations in terms of operating income and earnings before interest, taxes, depreciation and amortization. The Company's first production well, the Peyton 21-1, has been producing natural gas, natural gas liquids, and helium since August 17, 2022 at rates most recently over 100 mcf per day including approximately 500 cubic feet per day of helium. A pump has been installed and will begin moving the accumulated fluids to further open up the flow of gas which we expect will improve production from the Peyton 21-1 well. It should be noted that all three upper main pay zones have not yet been tested. Only the middle pay zone is currently being produced, with the addition of more pay zones in the future, the Company believes that production may be enhanced further. The helium concentration of our produced gas is approximating 0.5% which is accumulating in our account held by the processor and awaiting final sale. The Company has negotiated rates with potential retail buyers of its production with retail rates approximating $800 per MCF. Our agreement with the helium processor provides that we control our own destiny and may take our helium 'in-kind' at the tailgate of the plant. This enables us to sell our helium to wholesale and retail customers including industrial gas distributors at prevailing market rates throughout the world. AMGAS is working with its Hugoton Farm-out Venture partners to analyze the information obtained from the successful initial exploratory well drilling and completion to determine the timing and location of the drilling of its next exploratory well. AMGAS acquired a 60.7143% membership interest in GMDOC, LLC, , which had previously acquired working interests in certain oil and gas leases from Castelli Energy, L.L.C,. The GMDOC Leases cover approximately 10,000 acres located in Central and Southern Kansas near the Oklahoma border. The GMDOC Leases currently produce approximately 100 barrels of oil per day and 1.5 million cubic feet of natural gas per day on a gross basis. The GMDOC acquisition was effective April 1, 2022, therefore their operations have been included in AMGAS's financial statements for the second and third quarter of 2022. EBITDA for the third quarter 2022 were $585,852 and $995,211 for the three and nine months ended September 30, 2022. Results for both the nine months ended September 30, 2022 included approximately $100,000 of acquisition related fees and costs. The operating results for the three and nine months ended September 30, 2022 substantially exceeded our expectations and reflected the strong market prices for the sale of our produced oil and natural gas.

08:12 EST Antelope Enterprise Holdings enters into service contract with AI company - Antelope Enterprise Holdings' 51% owned subsidiary, Hainan Kylin Cloud has entered into a Service Agreement Contract with Anhui Zhongzhou Innovation to utilize its SaaS platform to help Anhui Zhongzhou recruit personnel for its artificial intelligence data services business. The one-year contract expires on October 16, 2023, and can be renewed thereafter. The Service Contract stipulates that Kylin Cloud will recruit part-time personnel for Anhui Zhongzhou to help in their business development associated with data collection, data labelling and data annotation services for AI and machine learning for their clients.

08:10 EST Chemomab Therapeutics' CM-101 shows efficacy in post-COVID lung injury - Chemomab Therapeutics announced that clinical data presented today showed that CM-101 was safe and well-tolerated and achieved reductions in biomarkers associated with lung inflammation and fibrogenesis in a clinical study in patients hospitalized with COVID-19-derived lung injury. CM-101 is in development for the treatment of fibro-inflammatory disorders, including primary sclerosingcholangitis - PSC - and systemic sclerosis - SSc -. The objective of the study was to evaluate the drug's safety and activity in hospitalized COVID-19 patients with severe pneumonia, including its impact on biomarkers related to lung inflammation. Administration of CM-101 was found to be safe and well tolerated. Rapid reductions in serum biomarkers of lung inflammation, fibrogenesis and neutrophil activity were observed post-treatment with CM-101, consistent with effects seen in previous preclinical and early clinical data. Reductions in the serum levels of biomarkers seen in the study included cytokines CXCL9 and CXCL10 that are highly associated with lung inflammation. CXCL10 was reduced by a median change of 65% from baseline as soon as 24-hours post treatment with CM-101 and further reduced by almost 80% at day 3. The effect was sustained through the end of the follow-up period. Treatment with CM-101 impacted biomarkers that are associated with the formation and degradation of the extracellular matrix, such as Procollagen 4 and C3M, which were highly elevated in these patients at baseline and were significantly reduced by a median change of 25% as soon as 72 hours post-treatment, a reduction that remained stable until the end of the follow-up period.

08:08 EST Braskem targets carbon neutrality by 2050 - Braskem announced significant progress towards securing renewable and emissions-free power for its North American production facilities. The company's current energy sourcing roadmap calls for more than a 15% reduction in carbon dioxide-equivalent emissions by 2030 with a path to carbon neutrality by 2050.

08:07 EST Chubb names Darryl Page as Chief Culture Officer - Chubb announced Darryl Page has been appointed Vice President, Chubb Group and Chief Culture Officer, succeeding Ivy Kusinga. In this role, he will oversee Chubb's culture and diversity, equity and inclusion strategy. Page is returning to Chubb after retiring in July 2022. The appointment is effective January 9, 2023. Page will report to John Keogh, President and Chief Operating Officer, and Jo Ann Rabitz, Senior Vice President, Chubb Group and Global Human Resources Officer.

08:05 EST Bluejay Diagnostics expects cash to fund operations for next 12 months - Cash and cash equivalents on September 30, 2022 were $13.3 million, as compared to $19.0 million on December 31, 2021. The Company has maintained a slow cash burn during its FDA submission process and currently expects that its cash position will be sufficient to fund operations for the next 12 months.

08:05 EST Elevance Health to acquire BioPlus, terms undisclosed - Elevance Health announced that it has entered into an agreement with CarepathRx, a portfolio company of Nautic Partners, to acquire BioPlus, a comprehensive specialty pharmacy. BioPlus provides a complete range of specialty pharmacy services for patients living with complex and chronic conditions, such as cancer, multiple sclerosis, hepatitis C, autoimmune diseases, and rheumatology. This acquisition will help Elevance Health meet the specialty drug needs of its clients and customers with a whole-health approach, supported by integrated programs across Elevance Health and Carelon, Elevance Health's healthcare services brand. The acquisition is subject to customary closing conditions and is expected to close in the first half of 2023. BioPlus is not expected to have a material impact on adjusted earnings per share in 2023.

08:01 EST International Seaways declares $1.00 per share special dividend - The Company's Board of Directors declared a special dividend of $1.00 per share of common stock on November 7, 2022. Dividends will be paid on December 22, 2022 to shareholders with a record date at the close of business on December 8, 2022.

07:58 EST Pure Sunfarms expands its brand portfolio, introduces soar Soar - Pure Sunfarms, a wholly owned subsidiary of Village Farms International, further expands its brand portfolio by introducing Soar, a cannabis brand designed to deliver an elevated cannabis experience with limited quantity batches of exotic and unique genetics that are hand-harvested, hang-dried, and hand-detailed. "Soar is joining our family of brands, which includes our BC grown flagship brand, Pure Sunfarms, and our newly introduced, bulk-sized value brand, the Original Fraser Valley Weed Co.," says Mandesh Dosanjh, President and CEO, Pure Sunfarms.

07:55 EST InflaRx initiates first-in-human study with INF904 - InflaRx announced that it has dosed its first healthy volunteer in a randomized, double-blind, placebo-controlled Phase I trial of orally administered, small molecule C5aR inhibitor INF904. This single ascending dose Phase I trial aims to evaluate the safety, tolerability and pharmacokinetics of INF904 in healthy volunteers. "Our preclinical studies with our new orally administered, small molecule C5aR inhibitor INF904 have shown potential for INF904 to inhibit C5a-induced signaling through its receptor C5aR. We are excited to enter clinical development of this new drug candidate," said Renfeng Guo, M.D., Chief Scientific Officer and Founder of InflaRx. "INF904 is a promising addition to our pipeline of candidates controlling the terminal complement C5a / C5aR pathway. As an orally administered compound, we plan to study if INF904 is especially suitable for patients suffering from complement-mediated chronic autoimmune and inflammatory diseases requiring ongoing long-term treatment," he added. In the Phase I first-in-human trial, InflaRx plans to initially enroll approximately 62 healthy volunteers who will be randomly assigned to receive INF904 or placebo. The study will assess single ascending doses under fasted conditions. The main objective of the trial is to assess safety and tolerability. Secondary endpoints include several pharmacokinetic parameters.

07:52 EST Boralex provides outlook - On June 17, 2021, Boralex's management unveiled the updated strategic plan that will guide its efforts to achieve new corporate targets for 2025. Boralex's 2025 Strategic Plan is built around the same four strategic directions as the plan launched in 2019 - growth, diversification, new customers and optimization - and six corporate targets. The details of the plan, which also sets out Boralex's corporate social responsibility strategy, are found in the Company's annual report. Highlights of the main achievements for the quarter ended September 30, 2022, in relation to the 2025 Strategic Plan can be found in the 2022 Interim Report 3, available in the Investors section of the Boralex website. In the coming quarters, Boralex will continue to work on its various initiatives under the strategic plan, including project development, analysis of acquisition targets and optimization of power sales contract management. On October 28, 2022, Boralex announced an update to its management model. The new decentralized model will enable the Company to be more proactive with its regional markets and closer to their specific realities. It will also allow it to make informed decisions faster and build on its competitive strengths, enabling it to continue to make its mark and take a different approach to growth in its business segment.

07:50 EST Reunion Gold announces new drill results from Oko West blocks 1, 4 - Reunion Gold announces additional high-grade intercepts from its Oko West project, including two holes that significantly expand the high-grade mineralized envelope below known mineralized zones. In the past few months, the Company has focused on infill drilling to a spacing required for resource estimation, expansion of the known mineralized footprint both at depth and along strike, and continued exploration work to the south of the Kairuni zone on blocks 5 and 6. Justin van der Toorn, the Company's VP Exploration, stated "As we shift from the infill program that will lead to a high confidence resource estimate down the road, we are seeing our deeper drill holes continuing to intersect significant high-grade mineralization. This, in turn, is guiding our focus of further resource definition drilling coverage that allows us to grow the size of the mineralized zones with systematic step-outs."

07:48 EST Stella-Jones announces 2022-2024 financial objectives - Stella-Jones' sales are primarily to critical infrastructure-related businesses. While all product categories can be impacted by short-term fluctuations, the business is mostly based on replacement and maintenance driven requirements, which are rooted in our customers' long-term planning. Corresponding to this longer-term horizon and to better reflect the expected sales run-rate for residential lumber and reduce the impact of commodity price volatility, in March 2022, the Company provided its financial objectives for 2022 to 2024. Below are key highlights of the 2022-2024 financial objectives with a more comprehensive version, including management assumptions, available in the Company's MD&A. Management remains confident in the achievement of its three-year strategic guidance. Key Highlights: Compound annual sales growth rate in the mid-single digit range from 2019 pre-pandemic levels to 2024; EBITDA margin of approximately 15% for the 2022-2024 period; Capital investment of $90 to $100 million to support the growing demand of its infrastructure-related customer base, in addition to the $50 to $60 million of annual capital expenditures; Residential lumber sales expected to stabilize between 20-25% of total sales while infrastructure-related businesses expected to grow to 75-80% of total sales by 2024; Anticipated returns to shareholders between $500 and $600 million during the three-year period; Leverage ratio of 2.0x-2.5x between 2022-2024, but may temporarily exceed range to pursue acquisitions.

07:45 EST Argo supports all 7 of its board nominees, opposes Capital Returns' candidates - Argo Group International Holdings announced that it is mailing a letter to shareholders in connection with its 2022 Annual Meeting of Shareholder urging them to vote the BLUE proxy card "FOR" ALL seven of Argo's highly qualified director nominees. The Annual Meeting will be held on December 15 , and shareholders of record as of October 26 are entitled to vote at the meeting. In the letter, Argo highlights its refreshed Board, which includes executives with relevant expertise, including experience across risk management, technology and cybersecurity, investment management and M&A and proven track records leading successful financial operations. The directors targeted by Capital Returns - Bernard Bailey and Al-Noor Ramji - bring expertise and experience important to the Company's business and have been instrumental in overseeing the execution of the Company's transformation, recruiting new management and refreshing the Board. In contrast, the Argo Board formally interviewed Capital Returns' candidates - Ronald Bobman and David Michelson - and unanimously concluded that appointing Messrs. Bobman and Michelson would diminish the Board's capabilities and expertise. To this point, Mr. Bobman has no public company Board experience, and the Board believes that any insurance background he may possess is already well represented in its composition. Mr. Michelson currently serves as an advisor or director of at least six other companies, one of which has suffered a ~98% stock price decline during his tenure as a director. Further, as reported in its own SEC filings, since April 2022, Capital Returns has been regularly selling blocks of Argo shares. This leads the Board to seriously question whether Capital Returns is a long-term investor in Argo, and if its nominees truly have the best interests of Argo's shareholders in mind.

07:44 EST Phillips 66 to increase share repurchase program by $5B - Phillips 66 will provide a plan to deliver higher shareholder distributions and increase shareholder value at its investor day meeting in New York. Lashier said that the company plans to return an additional $10B to $12B to shareholders between mid-year 2022 and the end of 2024 through a combination of dividends and share repurchases. The company's board of directors approved a $5B increase to its authorization to repurchase its common stock, which brings the total amount of share repurchases authorized by the board since 2012 to an aggregate of $20B. Phillips 66 is enhancing refining performance by taking necessary actions to increase reliability, improve market capture and reduce costs. Phillips 66 plans to increase adjusted EBITDA by $3B over the next three years. The company expects to achieve this growth through its proposed 87% interest in DCP Midstream, execution of Rodeo Renewed and other projects, as well as sustainable cost reductions from its business transformation. These actions will enable the company to increase distributions to shareholders, Lashier said, adding that the company is committed to disciplined growth and financial flexibility to drive returns and reward shareholders, now and in the future. "We are announcing a number of priorities designed to reward shareholders," said Mark Lashier, president and CEO of Phillips 66. "Thanks to our clear vision, core values and dedicated employees, we've enjoyed tremendous success since our inception 10 years ago. We will continue our track record of strong returns and growing distributions in a competitive and sustainable way. We have returned more than $30 billion to shareholders since the company's formation in 2012, in large part from our uniquely integrated and diversified assets in Midstream, Chemicals, Refining and Marketing."

07:42 EST OnBuy selects Nuvei for digital marketplace payments - Nuvei Corporation announces it has been selected by UK marketplace OnBuy as its payment partner to help the business execute on its growth initiatives in and beyond the UK. OnBuy is investing in new, innovation-led partnerships using latest technologies to support the marketplace's disruptive eCommerce model as it expands. The payment technology partnership with Nuvei is a key part of its growth strategy to cement its name as a trusted marketplace powerhouse in the UK. OnBuy will draw on more than 580 alternative payment methods Nuvei provides and its on-demand payment technology support. Card processing and acquiring are also part of a mix of payment technology services provided to OnBuy by Nuvei.

07:36 EST Hilton Grand Vacations sees FY22 adjusted EBITDA $1.03B-$1.05B - The company said, "The Company is raising its 2022 guidance for Adjusted EBITDA excluding deferrals and recognitions to be in a range of $1,025 million to $1,045 million."

07:36 EST Inspired Entertainment signs long-term partnership with the U.K.'s Betfred - Inspired Entertainment announced a new five-year contract with Betfred Group, a UK-based bookmaker that owns and operates over 1,400 betting shops in the UK with over 50 years of experience. As part of this agreement, Inspired will exclusively provide Betfred with fully integrated managed services for its entire estate of over 5,500 terminals, including installation, remote and field technology support, as well as platform and content deployment. In addition, Betfred has committed to the procurement of 5,000 new Vantage server based gaming ready cabinets throughout 2023.

07:34 EST Arbutus Biopharma expects cash to fund operations into 2Q24 - During the nine months ended September 30, 2022, the Company received a $40.0 million upfront payment from Qilu Pharmaceutical related to a technology transfer and license agreement for AB-729 in greater China, $15.0 million of gross proceeds from Qilu's equity investment in the Company and $9.2 million of net proceeds from the issuance of common shares under Arbutus's "at-the-market" offering program. These cash inflows were partially offset by $62.4 million of cash used in operations. The Company expects a net cash burn between $90 to $95 million in 2022, not including the $55 million of proceeds received from Qilu, and believes its cash runway will be sufficient to fund operations into the second quarter of 2024.

07:26 EST Chart Industries to acquire Howden for $4.4B - Chart Industries announced that it has signed a definitive agreement to acquire Howden, a leading global provider of mission critical air and gas handling products and services, from affiliates of KPS Capital Partners, LP. The purchase price is $4.4 billion and will be funded through a combination of cash and shares of a newly created class of preferred stock. The acquisition is subject to the receipt of certain regulatory approvals and the satisfaction of other customary closing conditions and is expected to close in the first half of 2023. The acquisition will result in estimated combined revenue of approximately $3.4 billion based on the trailing twelve months as of August 31, 2022. The purchase price represents 12.9x Howden's adjusted EBITDA for the 12 months ended August 31, 2022, or 8.5x including estimated annual cost synergies of $175 million to be achieved in the first 12 months of ownership. In addition to cost opportunities, Chart has identified significant commercial synergies that are expected to reach $350 million annually by year three. Howden, headquartered in the U.K., is a leading global provider of mission critical air and gas handling products providing service and support to customers around the world in highly diversified end markets and geographies. Howden manufactures highly engineered fans, compressors, rotary heat exchangers, steam turbines, and other air and gas handling products, services, and solutions. With over 160 years of experience as a world-class application engineering and manufacturing company, Howden enables customers to achieve environmental and operational targets and efficiencies, including decarbonization of operations. Chart and Howden have similar cultures and values, as well as a history of successful cooperation on multiple successful projects in the past. With over 11,650 employees and a presence in 35 countries, post-closing the combined company will scale to offer more complete solutions across the Nexus of Clean in broader geographies and markets, thereby providing customers a further opportunity to have a one-stop shop for their full solution needs. Our aligned cultures are committed to serving customers and increasing productivity, and the combined leadership team will represent a combination of talent from both organizations, with Jill Evanko, CEO and President of Chart running the combined business post-closing. Ross Shuster, Howden's CEO, will continue to serve as an advisor of the combined business for up to one-year following the closing of the acquisition to support Chart in its integration efforts. The acquisition purchase price of $4.4 billion will be funded through a mix of cash and shares of a newly created class of preferred stock, which may represent approximately $1.1 billion of the purchase price. Chart has $3.375 billion of fully committed bridge financing in place from J.P. Morgan and Morgan Stanley Senior Funding, Inc. Chart expects to pursue a long-term financing structure expected to include a combination of term loans, senior secured and unsecured notes. The Company will prioritize deleveraging to reduce its net leverage ratio to the high-2x range by the end of calendar 2024 and an ongoing target of 2.0 - 2.5x. In connection with its deleveraging plans, Chart does not intend to undertake any material acquisitions or share repurchases until its leverage ratio returns to targeted levels.

07:25 EST TScan Therapeutics announces upcoming milestones - Hematologic Malignancies Program: The Phase 1 umbrella trial for TSC-100 and TSC-101 is open for enrollment, and the Company will provide a progress update at the 64th American Society of Hematology Annual Meeting. The Company expects to enroll the first two cohorts in this trial in the first half of 2023 and plans to report interim data for this study by the end of 2023. Solid Tumor Programs: The Company plans to progress IND-enabling studies for its solid tumor programs and submit IND applications for two MAGE-A1 TCRs by the end of 2022. The Company plans to file INDs for HPV and PRAME in the first half of 2023 with two additional INDs to be filed by the end of 2023. The Company expects to release preliminary clinical safety data for the most advanced TCRs by the end of 2023.

07:23 EST Roche announces publication of STRONG-HF study - Roche announced publication of the Safety, Tolerability and Efficacy of Rapid Optimization of Heart Failure, STRONG-HF, study in patients hospitalized for acute heart failure. The study, which includes utilization of the Roche Elecsys NT-proBNP biomarker, was terminated early for superior efficacy in the active arm of the study versus the usual standard of care, as it was considered unethical to continue with usual care. Implementing the study's strategy in routine clinical practice, has the opportunity to significantly reduce all cause deaths or heart failure readmissions and increase quality of life for more heart failure patients. The results have been shared at the American Heart Association, AHA, Late-Breaking Scientific Session and published simultaneously in the Lancet. "We are very excited about the positive outcome of this Investigator Initiated Study, which Roche supported, as it has the potential to bring about a paradigm shift in the management of heart failure patients," said Thomas Schinecker, CEO of Roche Diagnostics. "It also emphasizes how diagnostic solutions like NT-proBNP, embedded in a therapeutic strategy, are an integral part of improving patient care." The STRONG-HF study outlines that guideline-recommended therapies for heart failure can be safely up-titrated at the end of an acute heart failure admission, and after discharge, under strict follow-up and assessment of signs and symptoms of congestive heart failure, renal function, potassium and Roche Elecsys NT-proBNP.

07:21 EST Tarsus Pharmaceuticals sees cash runway into at least 2026 - As of September 30, 2022, cash, cash equivalents and marketable securities were $226.6 million

07:19 EST Galera Therapeutics expects cash to fund operations into 2H23 - As of September 30, 2022, Galera had cash, cash equivalents and short-term investments of $42.8 million. Galera expects that its existing cash, cash equivalents and short-term investments will enable Galera to fund its operating expenses and capital expenditure requirements into the second half of 2023.

07:15 EST PolyPid implements cost reduction plan including 20% decrease in headcount - Implemented a cost reduction plan, including a 20% decrease in headcount across all departments, which is expected to extend available cash into the third quarter of 2023 in support of the Company's long-term growth strategy.

07:10 EST TC Energy sees 2022 comparable EBITDA higher than 2021 - Revised 2022 comparable EBITDA outlook to be higher than 2021, with an expected year-over-year growth rate of approximately 4%. 2022 comparable earnings per common share are expected to be consistent with 2021.

07:06 EST Target Hospitality announces $100M share repurchase program - To broaden the range of potential capital allocation initiatives, Target's board of directors has authorized a stock repurchase program for up to $100M. The authorization of the repurchase program is consistent with the company's strategic objectives of maintaining a strong balance sheet while simultaneously pursing value enhancing initiatives.

07:03 EST Wendy's reports Q3 U.S. systemwide sales growth of 7.7% - Reports Q3 International systemwide sales growth 18.3%; Global 8.9%.

06:54 EST Crypto names down in pre-market as bitcoin falls below $17,200 - Stocks levered to bitcoin prices are down in pre-market trading as the cryptocurrency had fallen below $17,200 overnight - its lowest level since late 2020. Bit Digital (BTBT) is down 4% at $1.01, Riot Blockchain (RIOT) is down 5% at $5.06, Marathon Digital (MARA) is down 5% at $9.44, MicroStrategy (MSTR) is down 6% at $199.00 and Coinbase Global (COIN) is down 5% at $48.34.

06:46 EST Capri Holdings announces new $1B share repurchase program - On November 9, the company announced that its Board of Directors approved a new share repurchase program of up to $1B of its outstanding ordinary shares, providing additional capacity to return cash to shareholders over the longer term. This new two-year program will replace the company's existing $1B share repurchase program which had $250M of availability remaining.

06:41 EST BitNile to distribute 7M shares of Giga-tronics to stockholders - BitNile Holdings (NILE) announced that its subsidiary Giga-tronics (GIGA), intends to complete a distribution of approximately 7M shares of GIGA's common stock beneficially owned by BitNile as a dividend payable to the stockholders of BitNile common stock. The distribution of the 7M GIGA Shares will occur as soon as practicable after GIGA has obtained the requisite regulatory approvals therefor, and in compliance with US federal securities laws. BitNile anticipates that, upon completion of the distribution, the BitNile shareholders as of the record date to be in conjunction with the distribution, will be able to sell the GIGA Shares from time to time in either public or privately negotiated transactions.

06:33 EST D.R. Horton raises quarterly dividend to 25c per share - The dividend is payable on December 12 to stockholders of record on December 2.

06:20 EST Innoviz Technologies to increase order book by more than 30% by the end of 2022 - The company said, "The Company has achieved its stated goal of winning at least one new series production award in 2022, and to date has delivered two. The Company expects to increase its forward-looking order book by more than 30% by the end of 2022 and has already delivered a 165% increase year to date. The Company has achieved its expected stated goal to secure 10 pre-production programs during 2022. To date, the Company has participated in 14."

06:17 EST Meta's Zuckerberg: Revenue outlook lower than expected at beginning of year

06:14 EST Ceva CEO Gideon Wertheizer to retire, Amir Panush to succeed - Ceva announced that CEO Gideon Wertheizer has chosen to retire at the end of 2022. The Ceva board of directors has unanimously appointed Amir Panush as CEO effective January 1, 2023. Wertheizer will continue to serve as an active member of Ceva's board of directors and will be employed in an advisory role in the near term to ensure a leadership transition. Panush was selected to succeed Wertheizer as CEO following an extensive search. Having been based in the U.S. for the past 17 years, Panush will relocate to Israel in the coming months.

06:14 EST Terran Orbital provides operational outlook - Terran Orbital reiterates its expectation to deliver all ten buses in 2022 to Lockheed Martin in support of the SDA Transport Layer Tranche 0 and has commenced work on the next forty-two satellites for Tranche 1, expected to begin delivering in 2023. To support the continuing expansion of manufacturing capacity, the Company expects to open its new Irvine, California manufacturing facility in 1Q23.

06:11 EST Meta CEO Zuckerberg announces plans to lay off 13% of staff - Mark Zuckerberg said in a message to employees: "Today I'm sharing some of the most difficult changes we've made in Meta's history. I've decided to reduce the size of our team by about 13% and let more than 11,000 of our talented employees go. We are also taking a number of additional steps to become a leaner and more efficient company by cutting discretionary spending and extending our hiring freeze through Q1. I want to take accountability for these decisions and for how we got here. I know this is tough for everyone, and I'm especially sorry to those impacted. At the start of Covid, the world rapidly moved online and the surge of e-commerce led to outsized revenue growth. Many people predicted this would be a permanent acceleration that would continue even after the pandemic ended. I did too, so I made the decision to significantly increase our investments. Unfortunately, this did not play out the way I expected. Not only has online commerce returned to prior trends, but the macroeconomic downturn, increased competition, and ads signal loss have caused our revenue to be much lower than I'd expected. I got this wrong, and I take responsibility for that... Everyone will get an email soon letting you know what this layoff means for you. After that, every affected employee will have the opportunity to speak with someone to get their questions answered and join information sessions. We will pay 16 weeks of base pay plus two additional weeks for every year of service, with no cap. We'll cover the cost of healthcare for people and their families for six months... While we're making reductions in every organization across both Family of Apps and Reality Labs, some teams will be affected more than others. Recruiting will be disproportionately affected since we're planning to hire fewer people next year. We're also restructuring our business teams more substantially. This is not a reflection of the great work these groups have done, but what we need going forward." Reference Link

06:08 EST Meta Platforms to let go more than 11,000 employees, says Zuckerberg

06:07 EST Adidas sees 'strong' bottomline improvement in 2023 - In 2023, the company expects the non-recurrence of the one-off costs of around EUR 500 million occurred in 2022 to have a positive impact on the net income development in the same magnitude. In addition, in light of the challenging market environment, adidas established a business improvement program to safeguard the company's profitability in 2023. As part of this program the company has launched several initiatives to mitigate the significant cost increases resulting from the inflationary pressure across the company's value chain as well as unfavorable currency movements. In total, the program, which will result in one-off costs of around EUR 50 million in the fourth quarter of 2022, is expected to compensate cost headwinds of up to EUR 500 million in 2023. In addition, it is expected to deliver a positive profit contribution of around EUR 200 million next year. The company sees a "strong" bottomline improvement in 2023.

06:05 EST Rockwell Medical reacquires distribution rights to hemodialysis concentrates - Rockwell Medical (RMTI) announced that the company is reacquiring its distribution rights to its hemodialysis concentrates products from Baxter (BAX) and has agreed to terminate the exclusive distribution agreement dated October 2, 2014. Exclusivity and other provisions associated with the distribution agreement terminate November 9, 2022 and the remaining operational elements of the agreement terminate December 31, 2022. Rockwell is the second largest supplier of life-sustaining hemodialysis concentrates products to dialysis clinics in the United States. Under the exclusive distribution agreement, Baxter distributed and commercialized Rockwell's hemodialysis concentrates products in the United States and certain other countries. Rockwell manufactured all hemodialysis concentrate products and provided customer service and order delivery to nearly all U.S. customers. Following the reacquisition of these rights, Rockwell will now be able to sell its hemodialysis concentrates products directly to dialysis clinics throughout the United States and around the world. Additionally, Rockwell will now be able to independently price its products, eliminate costs associated with manufacturing covenants, improve manufacturing efficiencies, realize the full benefits from those improvements, and develop, in-license, or acquire new products to develop a broader kidney care products portfolio. This will improve Rockwell's overall profitability and set the company on a positive growth trajectory. Collectively, this affords Rockwell the opportunity to expand its leadership position within a large market opportunity, which currently is valued at $380M and is anticipated to grow to approximately $500M by 2026 in the United States alone. Rockwell will pay Baxter a fee for the reacquisition of its distribution rights. This fee will be payable in two equal installments on January 1, 2023 and April 1, 2023. To ensure that customer needs continue to be met after January 1, 2023, Baxter and Rockwell are working closely together to transition customers' purchases of Rockwell's hemodialysis concentrates from Baxter to Rockwell. With the completion of this transaction, along with the company's expanded partnership with DaVita (DVA) announced earlier this year, and the launch of a number of new growth initiatives, Rockwell expects to achieve profitability in 2024. If successful, the company expects that its cash balance will be sufficient to fund operations going forward, thereby reducing its reliance on funding operations through raising money in the capital markets.

05:37 EST Wipro appoints Simmi Dhamija as COO APMEA - Wipro announced the appointment of Simmi Dhamija as the COO of the Asia Pacific, Middle East and Africa, or APMEA, strategic market unit. Dhamija will lead delivery and operations of the strategic market unit across its different regions and effectively support its profitable growth ambitions. She is a seasoned leader with over two decades of experience in the technology industry. She joins Wipro from Tech Mahindra, where she was the chief transformation officer leading strategic initiatives across digital transformation, M&A synergy, profit improvement, delivery modernization, key customer engagements, and managing 360-degree relationships with partners and ecosystem stakeholders. Prior to that, she has held various global leadership roles in strategy, delivery, operations, and talent development.

05:24 EST Procore announces launch in Germany - Procore announced its launch in Germany as it expands its international footprint.

05:13 EST Cognizant selected by VodafoneZiggo as managed services partner - Cognizant announced that it has been selected by VodafoneZiggo, a provider of fixed, mobile and integrated communication and entertainment services to consumers and businesses, as its managed services partner to consolidate and support VodafoneZiggo's operations of IT and virtualized mobile network infrastructure. This will enable VodafoneZiggo to improve the availability and reliability of its communications services through proactive monitoring of infrastructure operations, more accurate planning, and with faster deployments of new services to its more than five million mobile business and consumer customers in The Netherlands. As part of the five-year operations and maintenance agreement, Cognizant will simplify the current on-premise landscape through increased levels of automation designed to reduce the total cost of ownership and enable more efficient onboarding of VodafoneZiggo's standard as well as containerized and virtualized NFV infrastructure.